Gilead pounced to buy cell therapy company Kite in August last year for just under $12 billion, shortly before the biotech firm gained approval for its CAR-T cancer therapy Yescarta. Now Gilead is ...

Gilead’s (NASDAQ:GILD) Kite unit reported positive results from a five-year follow-up of a Phase 2 study for its cell therapy Yescarta in certain patients with non-Hodgkin lymphoma, or NHL.

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Gilead is building a pipeline outside of HIV and HCV through acquisitions. The acquisition of Kite (CAR-T therapy Yescarta) is beginning to generate significant sales growth as the drug is used in ...

Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year ... the Executive Vice President of Kite. Let me remind you that we will be making forward-looking statements.

Dr. Berger succeeds Merdad Parsey, MD, PhD. SANTA MONICA, Calif., December 09, 2024--Kite, a Gilead Company (Nasdaq: GILD), today announced results from a five-year follow-up analysis of ZUMA-5 ...

Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).